Clinical trials: Chronic Obstruct Airways Disease
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
This study will assess of the efficacy and safety of a once-daily, 50µg inhalation of NVA237 in moderate to severe chronic obstructive pulmonary disease (COPD) patients over 26 weeks treatment.
- Trial name
- GLOW7 (NCT01566604)
- Testing
- NVA237
- Where
- 32 sites in China, India and 2 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients
The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV48108.
- Trial name
- NCT02315144
- Testing
- TV48108
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- CIRRUS (NCT01233232)
- Testing
- AZD5069 50mg, AZD5069 80mg
- Where
- 8 sites in Bulgaria, Germany and 2 more
- Volunteers
- 109 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
- Trial name
- NCT00268216
- Testing
- Salmeterol 50mcg/ Fluticasone Propionate 500mcg
- Where
- 459 sites in United States, Argentina and 42 more
- Volunteers
- 6,228 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD
A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD
The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00056264
- Testing
- Infliximab
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Chronic Obstructive Pulmonary Disease
Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study
The purpose of this study is to determine steady-state efficacy and dose response profile and to assess safety and pharmacokinetic profile of nebulized EP-101(SUN101) after 7-day dosing using an investigational high efficiency…
- Trial name
- NCT01426009
- Testing
- EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease
Effects Of Oral Prednisolone On Bone Metabolism In Patients With Chronic Obstructive Pulmonary Disease
The aim of this study is to establish associations between blood and urine markers of bone metabolism with histomorphometric changes (changes in the actual bone structure) resulting from short term oral prednisolone treatment in…
- Trial name
- NCT00384306
- Testing
- prednisolone
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)
The purpose of this study is to compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are…
- Trial name
- INSTEAD (NCT01555138)
- Testing
- Indacaterol, Salmeterol
- Where
- 94 sites in Argentina, Colombia and 7 more
- Volunteers
- 581 people
- Sponsor
- Novartis Pharmaceuticals
COPD (Chronic Obstructive Pulmonary Disease), COPD
Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD
The purpose of this Phase IIa study is to evaluate the safety, efficacy, and pharmacokinetics of JKN2304 Inhalation Solution in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT07450482
- Testing
- JKN2304 Inhalation Solution, Formoterol Fumarate Inhalation Solution
- Where
- 8 sites in China
- Volunteers
- 42 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Chronic Obstructive Pulmonary Disease
A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose
This is a Phase I open-label, single center study to assess the PK and safety of BGF MDI 320/14.4/9.6 µg in subjects with moderate to severe COPD.
- Trial name
- NCT03250182
- Testing
- PT010
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease
This study will assess the safety and tolerability of QAT370 compared to tiotropium in patients with COPD.
- Trial name
- NCT00532350
- Testing
- QAT370, Tiotropium
- Where
- 3 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
The objective of this study is to investigate the effect of the interaction of Erythromycin (CYP3A4/5 moderate inhibitor) on the pharmacokinetic of CHF6001 (CYP3A4/5 substrate) in Healthy Volunteers.
- Trial name
- NCT06395610
- Testing
- CHF6001 DPI, Erythromycin
- Where
- Bulgaria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD)
Sodium Pyruvate Therapy in COPD Patients
In animal models, sodium pyruvate has been shown to be an effective anti-inflammatory agent, and in human studies sodium pyruvate has been shown to be a bronchodilating agent.
- Trial name
- NCT00262613
- Testing
- sodium pyruvate in 0.9% sodium chloride solution
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emphycorp
Chronic Obstructive Pulmonary Disease (COPD)
A Phase II Clinical Trial of TQC3721 Suspension for Inhalation
TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle relaxation and anti-inflammatory effects.
- Trial name
- NCT05292196
- Testing
- TQC3721 suspension for inhalation
- Where
- 11 sites in China
- Volunteers
- 59 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple dose of Zabofloxacin Tablet 400 mg.
- Trial name
- DW224-III-3 (NCT01658020)
- Testing
- Zabofloxacin, Moxifloxacin
- Where
- South Korea
- Volunteers
- 345 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IIIa, multicenter, randomized, stratified (reversibility status), double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25 micrograms (mcg) once daily (QD) compared with VI 25 mcg QD…
- Trial name
- NCT02105974
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 237 sites in United States, Bulgaria and 9 more
- Volunteers
- 1,621 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
European Multi-center Post Market Study of the IBV Valve System
The objective of this randomized, blinded, multicenter, controlled study is to compare the performance of the IBV Valve System (treatment group) to a control group receiving a sham bronchoscopy procedure without valve placement.
- Trial name
- IBV (NCT00880724)
- Testing
- IBV Valve
- Where
- 7 sites in Austria, Belgium and 4 more
- Volunteers
- 100 people
- Sponsor
- Olympus Corporation of the Americas
Pulmonary Disease, Chronic Obstructive
Dose Finding Study in COPD
The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
- Trial name
- NCT00122434
- Testing
- BEA 2180 BR, tiotropium
- Where
- 43 sites in United States, Belgium and 1 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to…
- Trial name
- GLOW4 (NCT01119937)
- Testing
- NVA237, Tiotropium
- Where
- 40 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
This study is open to adults aged 40 years and older who have chronic obstructive pulmonary disease (COPD) with ongoing symptoms.
- Trial name
- NCT07907991
- Testing
- Verducatib
- Volunteers
- 1,800 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.